Novo Nordisk Stock Falls As 2026 Outlook Signals Pricing Pressure, Slowing Sales

Core Viewpoint - Novo Nordisk's stock is experiencing a decline following the release of its 2026 sales and operating profit outlook, which indicates challenges in growth due to pricing pressures and competition in the market [1]. Group 1: 2026 Outlook - Novo Nordisk anticipates a reported sales and operating profit boost in 2026 from a $4.2 billion reversal of the 340B Drug Pricing Program in the U.S., with a $400 million exclusion in 2025 [2]. - Excluding this one-time item, the mid-point growth guidance for 2026 indicates a sales decline of -1% and an operating profit increase of 11% at constant exchange rates (CER) [2]. - Adjusted sales growth for 2026, excluding the 340B reversal, is projected to be between -5% and -13% at CER [2]. Group 2: Factors Impacting Sales Outlook - The sales outlook is negatively affected by lower realized prices, the "Most Favoured Nations" agreement in the U.S., patent expirations of semaglutide in certain markets, and increased competition [3]. - The CEO highlighted that Novo Nordisk will encounter pricing challenges in a more competitive environment in 2026 [3]. Group 3: U.S. Market Conditions - Current assumptions for the U.S. market reflect ongoing GLP-1 prescription trends, heightened competition, reduced Medicaid coverage for obesity drugs, and pricing pressures linked to the MFN agreement [4]. Group 4: 2025 Performance - In 2025, Novo Nordisk's sales rose by 10% to DKK 309.06 billion at CER, while operating profit increased by 6% to DKK 127.66 billion, falling short of earlier guidance [5]. - Net profit saw a slight increase to DKK 102.43 billion, with earnings per share reported at DKK 23.03 [5]. - U.S. sales were positively influenced by gross-to-net sales adjustments [5]. Group 5: Product Launch and Market Response - The Wegovy pill was launched on January 5, 2026, with total weekly prescriptions reaching approximately 50,000 by January 23, primarily driven by the 1.5 mg starter dose in the self-pay channel [6]. - As of the publication date, Novo Nordisk's stock price had decreased by 14.02% to $50.62 [6].